Rapamune Improves Outcomes of Severe H1N1 Pneumonia
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Severe H1N1 pneumonia with acute respiratory failure shows hyperactive immune cells
infiltration of lung. Rapamune, a mTOR inhibitor, modulates the immune response by blocking
activation of T- and B-cells. To investigate the clinical efficiency of rapamune in severe
H1N1 pneumonia with respiratory failure, this study was conducted.